Hideki Endoh

ORCID: 0000-0002-3567-0405
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research
  • Chronic Myeloid Leukemia Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Metastasis and carcinoma case studies
  • Estrogen and related hormone effects
  • Lung Cancer Diagnosis and Treatment
  • Kruppel-like factors research
  • Plant tissue culture and regeneration
  • Transgenic Plants and Applications
  • Histone Deacetylase Inhibitors Research
  • Radiopharmaceutical Chemistry and Applications
  • RNA Research and Splicing
  • Lung Cancer Research Studies
  • Dermatologic Treatments and Research
  • Peptidase Inhibition and Analysis
  • Tracheal and airway disorders
  • Neuroendocrine Tumor Research Advances
  • RNA modifications and cancer
  • Cytokine Signaling Pathways and Interactions
  • RNA and protein synthesis mechanisms
  • MicroRNA in disease regulation
  • Cancer Diagnosis and Treatment
  • Salivary Gland Tumors Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies

Saku Central Hospital
2012-2025

Harvard University
2017

Gunma University
2000-2013

Aichi Cancer Center
2003-2011

Astellas Pharma (Japan)
2007

Iwate Prefectural Central Hospital
2003

The University of Tokyo
1999-2002

Kindai University
1996-2002

Enanta Pharmaceuticals (United States)
2002

Molecular Oncology (United States)
2000

Abstract In this study, we report for the first time reduced expression of let-7 microRNA in human lung cancers. Interestingly, 143 cancer cases that had undergone potentially curative resection could be classified into two major groups according to unsupervised hierarchical analysis, showing significantly shorter survival after with (P = 0.0003). Multivariate COX regression analysis showed prognostic impact independent disease stage (hazard ratio 2.17; P 0.009). addition, overexpression...

10.1158/0008-5472.can-04-0637 article EN Cancer Research 2004-06-01

The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity ER activation function 1 (AF-1). This Ser phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and cells treated with epidermal growth factor (EGF) insulin-like (IGF) vivo. Overexpression MAPK (MAPKK) or guanine nucleotide binding Ras, both which activate MAPK, enhanced estrogen-induced antiestrogen (tamoxifen)-induced transcriptional wild-type ER, but not that a...

10.1126/science.270.5241.1491 article EN Science 1995-12-01

Abstract Recently it has been reported that mutations in the tyrosine kinase domain of epidermal growth factor receptor(EGFR) gene occur a subset patients with lung cancer showing dramatic response to EGFR inhibitors. To gain further insights role carcinogenesis, we sequenced exons 18–21 using total RNA extracted from unselected 277 who underwent surgical resection and correlated results clinical pathologic features. were present 111 (40%). Fifty-two in-frame deletions around codons 746–750...

10.1158/0008-5472.can-04-2818 article EN Cancer Research 2004-12-15

Purpose To evaluate the relationship between mutations of epidermal growth factor receptor (EGFR) gene and effectiveness gefitinib treatment in patients with recurrent lung cancer after pulmonary resection. Patients Methods We sequenced exons 18-21 EGFR using total RNA extracted from 59 who were treated for cancer. Gefitinib was evaluated by both imaging studies change serum carcinoembryonic antigen (CEA) levels. Results found 33 (56%). Of these mutations, 17 deletions around codons 746-750...

10.1200/jco.2005.00.992 article EN Journal of Clinical Oncology 2005-03-01

Abstract Purpose: Non–small cell lung cancers carrying activating mutations in the gene for epidermal growth factor receptor (EGFR) are highly sensitive to EGFR-specific tyrosine kinase inhibitors. However, most patients who initially respond subsequently experience disease progression while still on treatment. Part of this “acquired resistance” is attributable a secondary mutation resulting threonine methionine at codon 790 (T790M) EGFR. Experimental Design: We sequenced exons 18 21 EGFR...

10.1158/1078-0432.ccr-06-0714 article EN Clinical Cancer Research 2006-10-01

The estrogen receptor (ER) regulates the expression of target genes in a ligand-dependent manner. activation function AF-2 ER is located ligand binding domain (LBD), while N-terminal A/B (AF-1) functions ligand-independent manner when isolated from LBD. AF-1 and exhibit cell type promoter context specificity. Furthermore, activity human ERalpha (hERalpha) enhanced through phosphorylation Ser(118) residue by mitogen-activated protein kinase (MAPK). From MCF-7 cells, we purified cloned 68-kDa...

10.1128/mcb.19.8.5363 article EN Molecular and Cellular Biology 1999-08-01

The nuclear vitamin D receptor (VDR) is a member of superfamily and acts as ligand-dependent transcription factor. A family cotranscriptional activators (SRC-1, TIF2, AIB-1) interacts with activates the transactivation function receptors in way. We examined interaction VDR these coactivators that was induced by several analogs, since they exert differential subsets biological action through unknown mechanisms. Unlike other analogs tested, OCT (22-oxa-1α,25-dihydroxyvitamin D3) TIF2 but not...

10.1128/mcb.19.2.1049 article EN Molecular and Cellular Biology 1999-02-01

Insertion mutations in EGFR and HER2 both occur at analogous positions exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these seldom achieve clinical responses to dacomitinib afatinib, two covalent quinazoline-based inhibitors of or HER2, respectively. In this study, we investigated the effects specific 20 insertion from NSCLC that had clinically achieved a partial response after treatment. We identified Gly770 as common feature among drug-sensitive mutations....

10.1158/0008-5472.can-16-3404 article EN Cancer Research 2017-04-01

Recently, several expression-profiling experiments have shown that adenocarcinoma can be classified into subgroups also reflect patient survival. In this study, we examined the expression patterns of 44 genes selected by these studies to test whether their were relevant prognosis in our cohort as well, and create a prognostic model applicable clinical practice.Expression levels determined 85 patients quantitative reverse transcriptase polymerase chain reaction. Cluster analysis was...

10.1200/jco.2004.04.109 article EN Journal of Clinical Oncology 2004-02-27

CITED1, a CBP/p300-binding nuclear protein that does not bind directly to DNA, is transcriptional coregulator. Here, we show evidence CITED1 functions as selective coactivator for estrogen-dependent transcription. When transfected, enhanced activation by the ligand-binding/AF2 domain of both estrogen receptor-α (ERα) and ERβ in an manner, but it affected activities other receptors only marginally. bound ERα manner through its transactivating domain, this binding activity was separable from...

10.1101/gad.906301 article EN Genes & Development 2001-10-01

We have previously shown by cDNA cloning that a higher plant, Arabidopsis thaliana , possesses at least two CDC2 genes ( CDC2a and CDC2b ) similar to the cell‐cycle‐controlling cdc2 gene of Schizosaccharomyces pombe . To understand exon—intron organization these genes, genomic clones were isolated their nucleotide sequences determined. The coding 5′‐untranslated regions interrupted seven one introns, respectively, whilst contained three introns within portion. These intron positions partly...

10.1016/0014-5793(92)80592-5 article EN FEBS Letters 1992-06-08

Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related deaths worldwide. To improve the prognosis patients with NSCLCs, new and validated therapeutic targets are critically needed. In this study, we focused on F-box WD repeat domain containing-7 (FBXW7), an E3 ubiquitin ligase, that regulates degradation MCL1, Myc, cyclin E, TOP2A. Importantly, loss FBXW7 was associated increased sensitivity tumors to class I-specific histone deacetylase (HDAC) inhibitor, MS-275....

10.1158/1541-7786.mcr-13-0341 article EN Molecular Cancer Research 2013-10-29

Abstract Purpose To investigate the frequency and characteristics of pulmonary metastases from malignant melanoma presenting as ground-glass opacity nodules (GGNs) on chest computed tomography (CT). Material methods A total 354 patients with who underwent CT for staging or follow-up were selected. We reviewed images enrolled 87 lung metastases. Two radiologists evaluated nodularity (solid GGNs). Additionally, tumor doubling time disease type (mucosal, cutaneous, acral melanomas) analyzed....

10.1007/s11604-025-01745-1 article EN cc-by Japanese Journal of Radiology 2025-02-05

Pleomorphic carcinoma is one of the most difficult non-small cell lung cancers to treat with cytotoxic agents. Early recurrence after pulmonary resection common, and prognosis poor. Herein, we report a case pleomorphic effectively treated via molecular targeting. An 80-year-old man relapsed within six months undergoing left lower lobectomy for pathological stage IIB carcinoma. The initial treatment consisted carboplatin, pemetrexed, pembrolizumab, together opioids (for severe pain due...

10.7759/cureus.79073 article EN Cureus 2025-02-15

Abstract Methylation‐associated inactivation of RASSF1 , a putative tumor suppressor identified at 3p21.3, is reported in several cancers. We examined non‐small lung cancer (NSCLC) to search for clinical implications. RT‐PCR analysis showed no expression RASSF1A 12 20 cell lines. Loss correlated well with promoter methylation status these Sequence revealed 2 polymorphisms (codons 21 and 133) transcripts, but not RASSF1C transcripts. No somatic mutations were found. Of 7 lines K‐ras codon or...

10.1002/ijc.11184 article EN International Journal of Cancer 2003-06-02

Predicted postoperative forced expiratory volume in 1s (ppoFEV1) is estimated lung cancer patients before pulmonary resection, as well the clinical stage. This study aims to evaluate ppoFEV1 and ppo-vital capacity (ppoVC) on day 7 (POD7) compare results following video-assisted thoracic surgery (VATS) open thoracotomy procedures.Of 155 who underwent 70 had VATS; 30 muscle-sparing (anterior limiting (AL)); 55 postero-lateral (PL). VC FEV1 were measured POD7 compared with using analysis of...

10.1016/j.ejcts.2009.11.016 article EN European Journal of Cardio-Thoracic Surgery 2009-12-22
Coming Soon ...